Kindstar Globalgene Reshapes Board and Committees to Bolster Governance

Kindstar Globalgene Technology, Inc. ( (HK:9960) ) has shared an update.

Kindstar Globalgene Technology has announced an updated composition of its board of directors, effective March 27, 2026, confirming Dr. Huang Shiang as chairman and chief executive officer alongside a mix of executive, non-executive and independent non-executive directors. The company also detailed the new membership structure of its audit, remuneration and nomination committees, clarifying leadership and oversight responsibilities as it seeks to strengthen corporate governance and board accountability for shareholders and other stakeholders.

The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.

More about Kindstar Globalgene Technology, Inc.

Kindstar Globalgene Technology, Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the medical and biotechnology sector. The company focuses on specialized diagnostic and genetic testing services, positioning itself to serve healthcare providers and patients that require advanced clinical testing solutions in China and potentially broader Asian markets.

Average Trading Volume: 591,904

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.14B

Learn more about 9960 stock on TipRanks’ Stock Analysis page.